5-OH-DPAT

5-OH-DPAT
Names
	Preferred IUPAC name (6S)-6-(Dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol
Identifiers
CAS Number	68593-96-4 ;
3D model (JSmol)	Interactive image; Interactive image; Interactive image;
Abbreviations	5-OH-DPAT
ChEMBL	ChEMBL273273 ;
ChemSpider	9474597 (S) ; 150564 ;
MeSH	5-Hydroxy-2-N,N-dipropylaminotetralin
PubChem CID	11299620 (S); 12280580 (R); 172267;
CompTox Dashboard (EPA)	DTXSID801336109 ;
	InChI InChI=1S/C16H25NO/c1-3-10-17(11-4-2)14-8-9-15-13(12-14)6-5-7-16(15)18/h5-7,14,18H,3-4,8-12H2,1-2H3/t14-/m0/s1 Key: MDBWEQVKJDMEMK-AWEZNQCLSA-N ;
	SMILES Oc1cccc2c1CC[C@H](N(CCC)CCC)C2; CCCN(CCC)C1CCc2c(O)cccc2C1; CCCN(CCC)C1CCC2=C(O)C=CC=C2C1;
Properties
Chemical formula	C16H25NO
Molar mass	247.382 g·mol−1
log P	3.55
Acidity (pKa)	10.543
Basicity (pKb)	3.454
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

5-OH-DPAT is a synthetic compound that acts as a dopamine receptor agonist with selectivity for the D₂ receptor and D₃ receptor subtypes.^[1]^[2] Only the (S)-enantiomer is active as an agonist, with the (R)-enantiomer being a weak antagonist at D₂ receptors.^[3] Radiolabelled ¹¹C-5-OH-DPAT is used as an agonist radioligand for mapping the distribution and function of D₂ and D₃ receptors in the brain,^[4]^[5] and the drug is also being studied in the treatment of Parkinson's disease.^[6]^{[needs update]}

References

^ Seiler MP, Stoll AP, Closse A, Frick W, Jaton A, Vigouret JM (June 1986). "Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents". Journal of Medicinal Chemistry. 29 (6): 912–7. doi:10.1021/jm00156a007. PMID 3712381.
^ Johansson AM, Nilsson JL, Karlén A, Hacksell U, Svensson K, Carlsson A, Kenne L, Sundell S (July 1987). "C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation". Journal of Medicinal Chemistry. 30 (7): 1135–44. doi:10.1021/jm00390a004. PMID 3599021.
^ Karlsson A, Björk L, Pettersson C, Andén NE, Hacksell U (1990). "(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities". Chirality. 2 (2): 90–5. doi:10.1002/chir.530020206. PMID 1976017.
^ Mukherjee J, Narayanan TK, Christian BT, Shi B, Dunigan KA, Mantil J (July 2000). "In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate". Synapse (New York, N.Y.). 37 (1): 64–70. doi:10.1002/(SICI)1098-2396(200007)37:1<64::AID-SYN7>3.0.CO;2-F. PMID 10842352. S2CID 43878278.
^ Leung K (2006). "(R,S)-2-(N-Propyl-N-1'-[11C]-propyl)amino-5-hydroxytetralin". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641325.
^ Ackaert OW, Graan JD, Shi S, Vreeken R, Della Pasqua OE, Dijkstra D, Westerink BH, Danhof M, Bouwstra JA (January 2011). "The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis". Journal of Pharmaceutical Sciences. 100 (7): 2996–3009. doi:10.1002/jps.22492. PMID 21283984.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

[pmid3712381-1] Seiler MP, Stoll AP, Closse A, Frick W, Jaton A, Vigouret JM (June 1986). "Structure-activity relationships of dopaminergic 5-hydroxy-2-aminotetralin derivatives with functionalized N-alkyl substituents". Journal of Medicinal Chemistry. 29 (6): 912–7. doi:10.1021/jm00156a007. PMID 3712381.

[pmid3599021-2] Johansson AM, Nilsson JL, Karlén A, Hacksell U, Svensson K, Carlsson A, Kenne L, Sundell S (July 1987). "C3-methylated 5-hydroxy-2-(dipropylamino)tetralins: conformational and steric parameters of importance for central dopamine receptor activation". Journal of Medicinal Chemistry. 30 (7): 1135–44. doi:10.1021/jm00390a004. PMID 3599021.

[pmid1976017-3] Karlsson A, Björk L, Pettersson C, Andén NE, Hacksell U (1990). "(R)- and (S)-5-hydroxy-2-(dipropylamino)tetralin (5-OH DPAT): assessment of optical purities and dopaminergic activities". Chirality. 2 (2): 90–5. doi:10.1002/chir.530020206. PMID 1976017.

[pmid10842352-4] Mukherjee J, Narayanan TK, Christian BT, Shi B, Dunigan KA, Mantil J (July 2000). "In vitro and in vivo evaluation of the binding of the dopamine D2 receptor agonist (11)C-(R,S)-5-hydroxy-2-(di-n-propylamino)tetralin in rodents and nonhuman primate". Synapse (New York, N.Y.). 37 (1): 64–70. doi:10.1002/(SICI)1098-2396(200007)37:1<64::AID-SYN7>3.0.CO;2-F. PMID 10842352. S2CID 43878278.

[pmid20641325-5] Leung K (2006). "(R,S)-2-(N-Propyl-N-1'-[11C]-propyl)amino-5-hydroxytetralin". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641325.

[pmid21283984-6] Ackaert OW, Graan JD, Shi S, Vreeken R, Della Pasqua OE, Dijkstra D, Westerink BH, Danhof M, Bouwstra JA (January 2011). "The pharmacokinetics and pharmacological effect of (S)-5-OH-DPAT following controlled delivery with transdermal iontophoresis". Journal of Pharmaceutical Sciences. 100 (7): 2996–3009. doi:10.1002/jps.22492. PMID 21283984.

[1]

[2]

[3]

[4]

[5]

[6]

5-OH-DPAT

See also

References